A gallium silica glass composition is described. The glass can be used in variety of biomedical applications

Various examples are provided for magnetic particle imbedded nanofibrous membranes. In one example, among others, a nanofibrous membrane includes one or more electrospun nanofibers forming form a layer of nanofibers, and a plurality of magnetic nanoparticles embedded in the one or more electrospun nanofibers. In another example, a method includes generating one or more electrospun nanofibers including magnetic nanoparticles from one or more nozzles positioned over a substrate to form a magnetic nanofibrous layer, and affixing the magnetic nanofibrous layer to a support structure. In another example, a system includes a magnetic nanofibrous membrane affixed to a support structure, and a magnetic field generator configured to generate a magnetic field that passes through the magnetic nanofibrous membrane.

Various aspects of the present disclosure provide compositions including a water-insoluble therapeutic agent and a gallate-containing compound. Other aspects provide methods of using such compositions.

Various aspects of the present disclosure provide compositions including a water-insoluble therapeutic agent and a gallate-containing compound. Other aspects provide methods of using such compositions.

A composite comprising: a barrier, said barrier being configured to selectively pass water, and said barrier being degradable in the presence of water; a matrix material for disposition within said barrier, wherein said matrix material has a flowable state and a set state, and wherein said matrix material is degradable in the presence of water; and at least one reinforcing element for disposition within said barrier and integration with said matrix material, wherein said at least one reinforcing element is degradable in the presence of water, and further wherein, upon the degradation of said at least one reinforcing element in the presence of water, provides an agent for modulating the degradation rate of said matrix material in the presence of water.

The invention pertains to the use of mesenchymal stromal cells (MSC) in the treatment of bone disorders or injuries. The invention provides MSC and preparations of specifically pooled MSC for use in the manufacturing of bone graft material for implanting into or attaching to bones in order to enhance bone regeneration after surgery or injury, or to treat various bone disorders, such as osteonecrosis. The invention provides bone graft material, a method for its production, bone graft implants, and medical methods and uses of the inventive products.

A bone cement composition contains (a) the product of a polymerisation reaction between a high molecular weight dimethacrylate monomer having a molecular weight of at least 250 and bearing at least one hydrophilic group, a monofunctional methacrylate monomer having a molecular weight of not more than 250 bearing at least one hydrophilic group, an methacrylate monomer, and a polymer having a molecular weight of at least 200,000, and (b) an inorganic filler which is present in an amount of at least about 40% by weight, based on the total weight of the cement composition.

A method for making a porous devitalised scaffold suitable for use in repair of osseous, chondral, or osteochondral defects in a mammal comprises the steps of providing micronized extracellular matrix (ECM) tissue, mixing the micronized extracellular matrix with a liquid to provide a slurry, and freeze-drying the slurry to provide the porous scaffold. A porous scaffold suitable for use in repair of osseous, chondral, or osteochondral defects in a mammal and comprising a porous freeze-dried matrix formed from micronised decellularised extracellular matrix tissue is also described.

The present invention relates to settable compositions for use in surgery. The invention also provides related compositions, including surgical kits and packages, as well as methods of making and using the settable compositions.

Embodiments of the present technology include a graft for administration at a treatment site of a patient. The graft may include a human cadaveric bone material bonded together with a polymeric binder. The human cadaveric bone material may include demineralized bone particles. The demineralized bone particles may have an average diameter less than 1.1 mm, less than 750 μm, less than 500 μm, or less than 250 μm. The human cadaveric bone material may include non-demineralized bone, cancellous bone, and/or cortical bone in embodiments. In some embodiments, bone from animals other than humans may be used, and the patient may be an animal other than a human.